1500 related articles for article (PubMed ID: 23764390)
1. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Croze ML; Soulage CO
Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
[TBL] [Abstract][Full Text] [Related]
2. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
Genazzani AD; Prati A; Santagni S; Ricchieri F; Chierchia E; Rattighieri E; Campedelli A; Simoncini T; Artini PG
Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
[TBL] [Abstract][Full Text] [Related]
3. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Pizzo A; Laganà AS; Barbaro L
Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y
Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
Pustotina O; Myers SH; Unfer V; Rasulova I
Gynecol Obstet Invest; 2024; 89(2):131-139. PubMed ID: 38295772
[TBL] [Abstract][Full Text] [Related]
6. Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS.
Facchinetti F; Bizzarri M; Benvenga S; D'Anna R; Lanzone A; Soulage C; Di Renzo GC; Hod M; Cavalli P; Chiu TT; Kamenov ZA; Bevilacqua A; Carlomagno G; Gerli S; Oliva MM; Devroey P
Eur J Obstet Gynecol Reprod Biol; 2015 Dec; 195():72-76. PubMed ID: 26479434
[TBL] [Abstract][Full Text] [Related]
7. Insulin-induced activation of glycerol-3-phosphate acyltransferase by a chiro-inositol-containing insulin mediator is defective in adipocytes of insulin-resistant, type II diabetic, Goto-Kakizaki rats.
Farese RV; Standaert ML; Yamada K; Huang LC; Zhang C; Cooper DR; Wang Z; Yang Y; Suzuki S; Toyota T
Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11040-4. PubMed ID: 7972005
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Højlund K
Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
[TBL] [Abstract][Full Text] [Related]
9. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome.
Baillargeon JP; Diamanti-Kandarakis E; Ostlund RE; Apridonidze T; Iuorno MJ; Nestler JE
Diabetes Care; 2006 Feb; 29(2):300-5. PubMed ID: 16443877
[TBL] [Abstract][Full Text] [Related]
10. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
Artini PG; Di Berardino OM; Papini F; Genazzani AD; Simi G; Ruggiero M; Cela V
Gynecol Endocrinol; 2013 Apr; 29(4):375-9. PubMed ID: 23336594
[TBL] [Abstract][Full Text] [Related]
11. Inositol: history of an effective therapy for Polycystic Ovary Syndrome.
Bizzarri M; Carlomagno G
Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1896-903. PubMed ID: 25010620
[TBL] [Abstract][Full Text] [Related]
12. Relationships of plasma C-peptide and gender to the urinary excretion of inositols in older people.
Campbell WW; Ostlund RE; Joseph LJ; Farrell PA; Evans WJ
Horm Metab Res; 2001 Jan; 33(1):44-51. PubMed ID: 11280715
[TBL] [Abstract][Full Text] [Related]
13. Reflections on inositol(s) for PCOS therapy: steps toward success.
Nestler JE; Unfer V
Gynecol Endocrinol; 2015 Jul; 31(7):501-5. PubMed ID: 26177098
[TBL] [Abstract][Full Text] [Related]
14. Soy β-conglycinin improves glucose uptake in skeletal muscle and ameliorates hepatic insulin resistance in Goto-Kakizaki rats.
Tachibana N; Yamashita Y; Nagata M; Wanezaki S; Ashida H; Horio F; Kohno M
Nutr Res; 2014 Feb; 34(2):160-7. PubMed ID: 24461318
[TBL] [Abstract][Full Text] [Related]
15. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
16. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
Minozzi M; Nordio M; Pajalich R
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):537-40. PubMed ID: 23467955
[TBL] [Abstract][Full Text] [Related]
17. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Nordio M; Proietti E
Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
[TBL] [Abstract][Full Text] [Related]
18. The diabetic rat kidney mediates inosituria and selective urinary partitioning of D-chiro-inositol.
Chang HH; Choong B; Phillips AR; Loomes KM
Exp Biol Med (Maywood); 2015 Jan; 240(1):8-14. PubMed ID: 25060739
[TBL] [Abstract][Full Text] [Related]
19. The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment.
Cabrera-Cruz H; Oróstica L; Plaza-Parrochia F; Torres-Pinto I; Romero C; Vega M
Am J Physiol Endocrinol Metab; 2020 Feb; 318(2):E237-E248. PubMed ID: 31874063
[TBL] [Abstract][Full Text] [Related]
20. Inositols: From Established Knowledge to Novel Approaches.
Dinicola S; Unfer V; Facchinetti F; Soulage CO; Greene ND; Bizzarri M; Laganà AS; Chan SY; Bevilacqua A; Pkhaladze L; Benvenga S; Stringaro A; Barbaro D; Appetecchia M; Aragona C; Bezerra Espinola MS; Cantelmi T; Cavalli P; Chiu TT; Copp AJ; D'Anna R; Dewailly D; Di Lorenzo C; Diamanti-Kandarakis E; Hernández Marín I; Hod M; Kamenov Z; Kandaraki E; Monastra G; Montanino Oliva M; Nestler JE; Nordio M; Ozay AC; Papalou O; Porcaro G; Prapas N; Roseff S; Vazquez-Levin M; Vucenik I; Wdowiak A
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
